HRAS and renal cell carcinoma: The overexpression of HRAS could promote sunitinib resistance in RCC cells (Figure 6B, Supplementary Figure 6A), and the inhibition of HRAS by lonafarnib 35 could restore sunitinib sensitivity in RCC cells (Figure 6C, Supplementary Figure 6B).